SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " treatment " 1,573 found 🔀 AI-powered Shuffle
UVA Health leads nation in treatment of rare vascular condition in elite athletes
The medical team has treated over 100 patients for Iliac artery endofibrosis, a condition most often found in elite athletes.
Why some couples are combining a European vacation with their IVF treatments
A growing number of Americans are looking abroad, particularly to Greece and Spain, to escape the high cost of fertility treatments at home.
Anna Paquin slams Hollywood for its treatment of ‘pre-sexualized’ child stars after Hayden Panettiere’s death
Anna Paquin criticized Hollywood’s treatment of ‘pre-sexualized’ child stars after Hayden Panettiere died at 36: ‘We were not as protected...as we are supposed to be.’
Siemens Healthineers receives up to $31M to develop autonomous robot for remote stroke treatments
The funding, provided over five years, will go toward developing a robot capable of performing advanced endovascular procedures without direct human input.
Maryland launches court-ordered mental health care in Baltimore, some counties
Maryland health officials are rolling out a new and controversial program to help those with severe mental health challenges stay on top of their treatment -- by using a court order to mandate that those patients comply with their medical plans.
Lil Nas X’s bipolar diagnosis and the paradox of treatment
We continue to romanticize the symptoms of mental health problems, especially when we talk about achievement.
Orexins: the brain’s Ozempic moment?
Drugs that mimic hormones involved with wakefulness, attention and motivation could transform narcolepsy treatment, and offer hope for depression and ADHD
Regional Opioid Task Force Announcement
Date of Record: August 20, 2026The Regional Opioid Task Force is pleased to announce: Notification of Funding Opportunity for the Providing Access, Treatment, and Hope Grant Program as well as a Posit
Pages - Maryland Department of Health announces launch of Assisted Outpatient Treatment program
An official website of the State of Maryland.
HCM drug advances have been a breakthrough—but more invasive treatments are still vital
Some HCM experts are concerned about the potential loss of surgical and interventional expertise as procedural volumes decline.
AHA says new legislation would strengthen stroke care and prevention
Sen. Ben Ray Luján, a stroke survivor, introduced the new bill. If passed, it would direct the federal government to study how stroke care is delivered in the United States and fund efforts aimed at improving treatments, data collection and public awareness.
What to know about the outbreak of a rare kind of Ebola
Bundibugyo virus is a rare type of Ebola that has no approved vaccine or treatment.
HHS announces addition of behavioral health programs eligible for federal reimbursement
The Department of Health and Human Services Aug. 18 announced that its Administration for Children and Families has added two new peer support programs to the Title IV-E Prevention Services Clearinghouse, allowing all states to claim federal reimbursement. One addition is the Family-Based Recovery program, which focuses on in-home clinical treatment for parents combatting addiction who have children ages 0-5.
Scientists turn probiotic bacteria into tiny drug factories for pancreatic cancer
Engineered probiotic bacteria were able to infiltrate pancreatic tumors, stimulate cancer-fighting immune cells, and slow tumor growth in animal studies. Even more strikingly, the treatment worked better when combined with chemotherapy, radiation, or immunotherapy.
UConn Startup Acquired by Leading Animal Health Company
New materials offer promising arthritis treatment for dogs and horses
Judge wants records on alleged cop-killer’s mental health: I-Team
A Cuyahoga County Common Pleas judge has ruled that a mental health treatment center must turn over all medical records on Delawnte Hardy, the man accused of killing Cleveland Police Officer Jamies…
Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening
Hypertension Research - Cost-effectiveness analysis of early antihypertensive treatment for hypertension detected at health screening
Former Mother-in-Law Describes Lindsay Clancy’s Mental Health Struggle in Murder Trial
Ms. Clancy, who is on trial for murder in the deaths of her three children, tried to find treatment for her deteriorating condition, her ex-husband’s mother testified.
Inside Caron Treatment Center’s C-Suite Shakeup
At least five top leaders at Caron Treatment Centers have parted ways with the company as part of a leadership shakeup that played out during the
Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling
The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.
WHO/UNICEF report highlights gaps in health facility sanitation
Despite notable gains since 2015, only four in ten facilities meet basic sanitation standards and fewer than six in ten achieve basic environmental cleaning standards such patient rooms and wards, operating theatres, examination and treatment areas, toilets and sanitation facilities, leaving patients and health workers exposed to preventable health risks.
Connecting a primary care patient with behavioral health treatment could be a phone call away
A statewide referral network could ease burdens and improve access to behavioral healthcare treatment services for Rhode Islanders amid a primary care shortage.
Atlanta teen with autism uses basketball tournament to raise money for youth mental health
According to America’s Health Rankings, Georgia ranks 47th in the country for the percentage of children who receive needed mental health treatment or counseling.
A little-known protein may be fueling Alzheimer’s — and scientists found a way to block it
An experimental Alzheimer’s compound prevented damaging protein clumps from forming in the brains of mice, helping nerve cells survive longer and reducing amyloid buildup. The treatment also appeared to improve heart health and slow some signs of aging, raising hopes for an entirely new way to combat dementia.
Healing Thyself: Managing Moral Injury in Healthcare
One of the most challenging parts of working in medicine is maintaining your own emotional health. New research on moral distress and moral injury offers clues on how we can better support healthcare workers.
This 10-cent heart drug cuts hospitalizations by 25%
A centuries-old heart drug costing less than ten cents a day could help keep heart-failure patients out of the hospital. New research suggests low-dose digoxin can reduce heart-failure hospitalizations by about 25%, potentially paving the way for its return as a major treatment.
Science & Medicine: San Antonio's fungus lab is on the front line of a growing drug-resistance crisis
When doctors can't identify a fungal infection, they often turn to UT Health San Antonio's Fungus Testing Laboratory, which has discovered more than 60 new species since 2013. The lab is now racing to fight drug-resistant fungi while helping bring new antifungal treatments to market.
How Iowans feel about Trump's tariffs, Canada's treatment as Republicans vie for support
Much like the Calgary Stampede in Canada, the Iowa State Fair is a crucial stop for politicians to meet voters, making it a hotbed for political debates — especially when U.S. midterms are coming up. And this year, one of the topics on Iowans' minds is U.S. President Donald Trump's trade war.
Business People
Benjamin Schurhamer, MD, recently joined Washington Regional Ozark Urology, where he provides diagnosis and treatment of urological conditions with a focus on cancers of the prostate, bladder and kidney.
Five remaining US detainees in Russia facing dire health concerns, horrific treatment: Gilman family rep
Kieran Ramsey, Chief Investigative Officer for Global Reach and a former FBI hostage recovery expert details the declining health of five Americans in Russian detention, arguing all five must be given wrongful detainee status.
Scientists solve the mystery of a brain “switch” that can trigger weight loss in opposite ways
Scientists have uncovered why two seemingly opposite ways of targeting the same brain receptor can both promote weight loss. In mice, activating the GIP receptor in the brainstem reduced appetite, while blocking it in the hypothalamus removed a kind of “brake” on fullness signals. The discovery helps explain why very different obesity drugs can achieve similar results and suggests that carefully combining GIP-targeting treatments with GLP-1 drugs like those related to Wegovy and Ozempic could produce stronger effects.
All hail Lambo’s new king! It’s the 1,050bhp V12-engined Revuelto SV
Hybrid Lamborghini gets the SV treatment and takes tech from the Fenomeno. Will be limited to 1,963 units
Gallery: Baptist Health Walker opens pediatric ER space, reopens NICU services
Baptist Health Walker Hospital has opened a new dedicated pediatric emergency room treatment space and reopened its Level II NICU services.Hospital leaders cut
Wisconsin prisons are struggling to improve mental health care
The Wisconsin Department of Corrections reports obstacles in the way of recommended reforms to prison mental health treatment
When is a mental health crisis too severe for telehealth? Warning signs families shouldn't ignore
Lindsay Clancy's psychiatrist had 14 virtual visits but never met her in person, raising questions about telehealth mental health treatment limits.
More than 80% of Georgia parents want more school-based mental health screening, treatment
Georgia parents overwhelmingly support school-based mental health services to help address the nation’s youth mental health crisis.
Promising research for ALS treatment underway at Temple Health in Philadelphia
Medtronic veteran named CEO of medtech startup Versa Vascular
Bill Shields, who spent a 15 years with Medtronic’s structural heart division, will now be helping lead a startup focused on tricuspid valve treatments.
New AI health effort takes aim at Hepatitis C
AI will be used to help expand treatment rates for Hepatitis C, HIV, and other conditions.
'GMA's Ginger Zee Opens Up About Surprise Health Struggle
The meteorologist took fans inside her treatment process.
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
In China, treatment for mental-health problems is a luxury
The government wants to improve a patchy and uneven systyem
What patients actually think about ‘minimally invasive’ brain implants
A new study polled people with treatment-resistant depression about what matters to them when it comes to brain implants for mental health.
How Nevada made big strides to keep kids with behavioral health issues out of institutions
Four years ago, the federal government found the state was sending too many kids out of state for treatment. That number has been cut by more than half.
Duke's digital twin technology could take hemodynamic assessments to a whole other level
Researchers at Duke are hard at work on digital twins that could help care teams make important treatment decisions.
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights
U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis...
As Candida auris spreads, UT Health San Antonio scientist highlights growing threat of antifungal resistance
As cases of Candida auris spread across the country and an UT Health San Antonio expert says better surveillance, awareness and new treatments will be critical to confronting the growing threat.
The Lindsay Clancy case shows the limits of postpartum psychiatry
“Our understanding and treatment of postpartum psychiatric illnesses remain profoundly inadequate,” experts write.
The Lindsay Clancy case shows the limits of postpartum psychiatry
“Our understanding and treatment of postpartum psychiatric illnesses remain profoundly inadequate,” experts write.
Small Business Spotlight: Specialty dental practice takes root on Market St.
WHAT MADE YOU WANT TO OPEN BLUE HERON ROOT CANAL SPECIALISTS? OWNER SARAH ERMOSHKIN: “I’ve always been an entrepreneur at heart. When I was 23 years old, I owned a cafe in Seattle, where I even fought to oppose oppressive sales taxes on espresso drinks. After selling that business, I got married and started a family. Once my children were in school, I attended dental school through the Navy Health Professions Scholarship Program (HPSP), which covered my tuition and provided a stipend. From the beginning, my goal was to eventually own my own practice after completing my military service. The work I do is incredibly rewarding and being able to create an environment that puts patients first while helping employees grow professionally makes every day as a business owner meaningful.” WHAT DOES YOUR BUSINESS PROVIDE? ERMOSHKIN: “Endodontists are often called ‘pain doctors’ because our primary mission is to relieve pain and save natural teeth. We specialize in root canal therapy, retreatment of nonhealing root canals, treatment of root resorption, apicoectomies – microsurgical root-end procedures – and vital pulp therapy for children. Our goal is to preserve teeth that might otherwise need to be extracted and replaced with implants. Saving a patient’s natural tooth is almost always the best long-term solution for their oral health.” HOW DOES YOUR MILITARY TRAINING HELP YOUR BUSINESS? ERMOSHKIN: “My military service taught me how to lead, collaborate and make decisions under pressure. I worked closely with senior leadership while treating a large patient population and collaborating with specialists across multiple disciplines. During the COVID-19 pandemic, (I) served a dual role as Navy dentist and as the public affairs officer for Naval Health Clinic Annapolis, where I helped develop medical and dental communications for the midshipmen and support staff, while coordinating with the broader Navy Capital Region. We worked closely with other military treatment facilities to share best practices and deliver consistent public health messaging. Those leadership experiences continue to shape how I lead my team and serve our patients today.” WHAT CHALLENGES ARE YOU FACING RIGHT NOW IN YOUR BUSINESS? ERMOSHKIN: “One of our biggest challenges is overcoming the misinformation surrounding root canal treatment. Root canals are safe, effective and often the best way to relieve pain while preserving a natural tooth. Unfortunately, many people choose extraction because they believe it’s less expensive or because they’ve seen misleading information online. What they may not realize is that losing a tooth can lead to shifting teeth, changes in the way they bite and chew and significantly higher costs to restore their smile later.”
Scientists discover a hidden brain rhythm that could improve Parkinson’s treatment
Scientists have pinpointed a brain network—and its distinctive electrical rhythm—that appears to drive the benefits of deep brain stimulation for Parkinson’s disease. The discovery could lead to more precise, personalized stimulation settings and better results for patients.
India plans insurance reforms to rein in healthcare costs, sources say
India is weighing wide-ranging reforms of health insurance, from benchmarked treatment rates to a nationwide claims exchange, as it looks to boost transparency in a struggle to hold down some of the highest medical inflation in Asia, two sources said.
Russia releases former US Marine reported in poor health
Robert Gilman, who was arrested in 2022, was left in "life-threatening condition" after being subjected to "harsh and abusive treatment", his family says.
USC Scientists Are Using Quantum Computing to Rethink Cancer Detection - USC Viterbi
By combining quantum computing with artificial intelligence, USC researchers are laying the groundwork for medical imaging tools that could help doctors diagnose cancer and plan treatments more precisely
Lindsay Clancy murder trial continues with focus on her mental health treatment
When a physician’s ‘noble’ reassurance leads to a patient’s unsought treatment
When a doctor tells a patient that his or her symptoms are normal within some given context, the patient may ignore the contextualization and only hear “You’re normal.” As shown in a new study, the partially received message can be a problem.
Long list of embarrassing WNBA incidents is what happens when sports leagues made politics their primary focus
From Caitlin Clark's treatment to Sophie Cunningham's stance on trans athletes, the WNBA's political battles are overshadowing the sport itself.
Long list of embarrassing WNBA incidents is what happens when sports leagues made politics their primary focus
From Caitlin Clark's treatment to Sophie Cunningham's stance on trans athletes, the WNBA's political battles are overshadowing the sport itself.
What to know about perimenopause and menopause
Discussing the transition, symptoms and treatments available for people going through menopause or perimenopause.
How Jefferson Health is testing new treatment for brain disorder: "It's amazing"
AbCellera women’s health data top ‘most aggressive upside scenario,’ putting Astellas and Bayer on notice
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market. The phase 2 clinical trial compared ABCL635, an antibody targeting NK3R, to placebo in patients with hot flashes caused by menopause. Investigators enrolled 92 postmenopausal women experiencing a mean of about 10 moderate or severe hot flashes per day. By Week 4, the number of moderate or severe hot flashes had fallen by a mean of 8.8 on ABCL635 and by 3.5 on placebo. That statistically significant, placebo-adjusted reduction of 5.3 hit the trial’s primary endpoint. The level of efficacy also cleared the bar set by existing drugs. While cross-trial comparisons can be misleading, AbCellera CEO Carl Hansen, Ph.D., had seen enough to start hyping the program. “We now view ABCL635 as a potential best-in-class non-hormonal therapy with strong differentiation against approved NK3R competitors across all important dimensions, including efficacy, safety, dosing and convenience,” Hansen said on a Monday morning conference call with investors to discuss the data. “We believe ABCL635 is now a highly de-risked program.” Last week, Hansen used AbCellera’s earnings call to set expectations for readout, with the CEO defining success as a clean safety profile and efficacy comparable to the two approved small molecules. The data vaulted over that bar. Astellas linked (PDF) one of the small molecules, Veozah, to placebo-adjusted reductions in hot flash frequency of 2.1 and 2.6 at Week 4 of its two phase 3 trials. Bayer reported (PDF) placebo-adjusted reductions of 3.04 and 3.29 at Week 4 of pivotal studies for its small molecule, Lynkuet. At 5.3, the placebo-adjusted reduction in AbCellera’s trial comfortably cleared the standard set by the incumbents. Veozah and Lynkuet came to market based on evidence of their ability to reduce the frequency and severity of hot flashes. AbCellera’s phase 2 study covered both endpoints, with the Canadian biotech reporting a mean reduction in severity of 1.4 points at Week 4 on ABCL635, compared to 0.3 points for placebo. Again, the placebo-adjusted result compares favorably to data on Veozah and Lynkuet. Analysts shared Hansen’s enthusiasm for the data. The phase 2 results “firmly validate ABCL635 as a potentially best-in-class treatment,” BMO Capital Markets analysts said in a note to investors Monday. ABCL635’s apparent efficacy edge “is likely attributable to the higher dosing/target engagement the asset is able to reach vs. the oral agents due to its wider therapeutic index,” the analysts added. The analysts, who model $2.3 billion in unadjusted peak sales for ABCL635, flagged the safety profile as another positive of the phase 2 readout. While Veozah carries a boxed warning for liver damage, nobody on ABCL635 in the phase 2 trial had elevated liver enzymes or bilirubin values. If replicated in phase 3, the lack of a liver signal could allow approval without the monitoring requirements imposed on Veozah. Investors appeared equally enthused, sending AbCellera's stock up 32% to $9.21 in premarket trading Monday from a Friday closing price of $6.93. Next, AbCellera will collect the Week 12 data and talk to its advisors about further development. The results open up “a wide variety of possibilities of how we might take this forward into phase 3 studies to truly maximize the value of the asset and make sure that ABCL635 is able to demonstrate its differentiation potential,” Sarah Noonberg, M.D., Ph.D., AbCellera’s chief medical officer, told investors.
Lindsay Clancy murder trial resumes with mental health treatment in focus
Former FBI special agent James Gagliano joins 'Fox & Friends First' to discuss the resumption of the Lindsay Clancy murder trial in Plymouth, Massachusetts, focusing on the defense's insanity plea.
Bride-to-be sounds alarm after popular beauty treatment left her disfigured before the big day
Tommy John misses Old-Timers' Day to continue cancer treatment
NEW YORK – Tommy John, whose Major League pitching career was extended by a revolutionary elbow procedure that now carries his name, penned an emotional statement addressing the Yankees and their fans ahead of Saturday’s Old-Timers’ Day festivities at Yankee Stadium. “I want to thank the Yankees organization and the
A tragedy & a trial shine a spotlight on new moms’ mental health
The Lindsay Clancy trial shines a spotlight on postpartum psychosis and other forms of perinatal mental health issues; treatment and education are vital and available
Missouri should dump the use of junk science in its courtrooms
Missouri patients deserve confidence that the science presented in our courtrooms is credible, reliable and grounded in evidence. When unreliable expert testimony is allowed to influence juries, the consequences extend far beyond the courtroom. Manufactured claims can scare patients away from proven treatments and make medical innovators think twice about investing in research and development […]
Allegheny Health Network first in Western Pa. to offer GammaTile brain cancer treatment
Trailblazing technology offered at Allegheny General Hospital in Pittsburgh’s North Side is helping patients with operable brain metastases live longer. Allegheny Health Network neurosurgeon Matthew J. Shepard is the first physician in Western Pennsylvania to use GammaTile, an FDA-approved treatment that uses collagen disks about the size of postage stamps
AI just created a virus not found in nature and scientists are worried
The technique could lead to new treatments for antibiotic-resistant bugs, but some scientists say the technology could be misused
Vitamin C may fight cancer — but not the way scientists once thought
Linus Pauling was widely mocked for claiming that vitamin C could fight cancer, especially after trials using vitamin C pills showed no benefit. Researchers now know that intravenous vitamin C reaches vastly higher concentrations and can behave more like an experimental cancer drug than an ordinary supplement. Early studies suggest it may damage vulnerable cancer cells, reduce treatment side effects, and possibly improve outcomes for some patients.
Business Restructuring Review Vol. 25 No. 4 July-August 2026
In This Issue New York Bankruptcy Court: Premature Allegations of Creditor Mistreatment Insufficient to Deny Chapter 15 Recognition of Foreign Restructuring Proceeding In In re ARD Finance, S.A., No. 25-12794 (MG), 2026 WL 817458 (Bankr. S.D.N.Y. Mar. 25, 2026), the U.S. Bankruptcy Court for the Southern District of New York was presented with a petition seeking chapter 15 recognition of Luxembourg's recently enacted bankruptcy law governing judicial reorganization proceedings. The court granted the petition, turning aside challenges to recognition voiced by a creditor group arguing that recognition should be denied based upon allegations of unfairness to creditors in the Luxembourg proceeding that would make recognition manifestly contrary to U.S. public policy. According to the bankruptcy court, recognition was warranted because: (i) the rules and procedures governing the proceeding under Luxembourg law were fundamentally fair; (ii) the petition otherwise satisfied chapter 15's recognition requirements; and (iii) the creditor group's allegations were premature, given the fact that the Luxembourg court presiding over the debtor's restructuring proceeding had not confirmed a restructuring plan, and all creditors had the right to participate fully and voice their objections in the proceeding (including the right to appeal an order approving a plan). [read more …] Florida Bankruptcy Court Examines Scope of Discovery in Chapter 15 Cases In In re Banco Master, S.A., No. 25-24568-SMG, 2026 WL 931729 (Bankr. S.D. Fla. Apr. 6, 2026), the U.S. Bankruptcy Court for the Southern District of Florida granted in part and denied in part post-recognition motions filed by an insider of a foreign debtor seeking to bar or limit discovery sought by the debtor's foreign representative concerning allegedly voidable transfers involving the debtors' U.S. real property. According to the court: (i) although chapter 15 includes its own discovery provisions among the relief that may be granted to a foreign representative, the expansive discovery available in cases under other chapters of the Bankruptcy Code is also available in chapter 15 cases; (ii) the discovery sought by the foreign representative was permissible; (iii) discovery regarding matters that were the subject of a pending adversary proceeding had to be undertaken under the more restrictive rules applicable to such proceedings; and (iv) a discovery request would be barred to the extent that it sought production of documents or testimony from a subpoenaed entity that exceeded the geographic limitations specified in such rules. [read more …] Delaware District Court Affirms Chapter 15 Recognition Order Enforcing Nonconsensual Third-Party Releases In U.S. Int'l Dev. Fin. Corp. v. Credito Real S.A.B. de C.V. SOFOM, E.N.R. (In re Credito Real S.A.B. de C.V. SOFOM, E.N.R.), 677 B.R. 192 (D. Del. 2026), appeal filed, No. 26-2356 (3d Cir. June 5, 2026), the U.S. District Court for the District of Delaware affirmed a bankruptcy court order granting chapter 15 recognition to a Mexican "concurso mercantile" proceeding and enforcing nonconsensual third-party releases approved by the Mexican court. Agreeing with the bankruptcy court that the releases were not manifestly contrary to U.S. public policy, the district court concluded: "It is well settled that U.S. bankruptcy courts can give effect to foreign orders in recognized foreign proceedings pursuant to the authority granted in Chapter 15, even when those orders contain relief unavailable under U.S. law. [The appellant's] arguments misconstrue the Supreme Court's narrow holding in Purdue, applicable in Chapter 11 cases, as well as the statutory framework of Chapter 15 and its core policy objectives. Accordingly, I will affirm the Enforcement Order." The ruling has been appealed to the U.S. Court of Appeals for the Third Circuit. [read more …] Fifth Circuit: Bankruptcy Court, Not State Court, Had Jurisdiction to Allow or Disallow Administrative Expense Claim In Storey Minerals Ltd. v. EP Energy E&P Co., LP (Matter of EP Energy E&P Co., LP), 169 F.4th 609 (5th Cir. 2026), the U.S. Court of Appeals for the Fifth Circuit affirmed lower courts' rulings disallowing a creditor's administrative expense claim. It also rejected the creditor's argument that, because the claims were predicated on state law, a state court should adjudicate the merits of the state law causes of action before the bankruptcy court could allow or disallow the claim as an administrative expense. According to the Fifth Circuit, even though the causes of action were based on state law, the bankruptcy court had jurisdiction to determine whether the creditor's claims should be conferred with administrative expense priority in the debtors' chapter 11 case. [read more …] New York Bankruptcy Court: Dismissal of Involuntary Chapter 11 Case Filed Prior to Commencement of Foreign Restructuring Proceeding Unwarranted In In re Xinyuan Real Estate Co. Ltd., No. 25-10745 (PB), 2026 WL 592250 (Bankr. S.D.N.Y. Mar. 3. 2026), the U.S. Bankruptcy Court for the Southern District of New York considered the bona fides of an involuntary chapter 11 petition filed by certain holders of U.S. dollar-denominated notes against a holding company for a group of Chinese property development companies that filed a restructuring proceeding in the Cayman Islands after the noteholders filed the involuntary chapter 11 petition. The court denied the debtor's motion to dismiss the chapter 11 case. Given the timing of the filing of the Cayman Islands restructuring proceeding, the absence of any progress in the proceeding for seven months, the debtor's need to restructure notes governed by U.S. law, and the debtor's lack of any meaningful contacts to the Cayman Islands, dismissal of the chapter 11 case was unwarranted under the applicable provision of the Bankruptcy Code, international comity, or the doctrine of forum non conveniens. [read more …] Bankruptcy Court Evaluates Trustee's Authority to Sell Avoidance Actions and Right of Target Defendants to Object In In re Law Enf't Officers Sec. Union, No. 24-70277-JAD, 2026 WL 560452 (Bankr. W.D. Pa. Feb. 27, 2026), a chapter 7 trustee sought court approval to sell certain avoidance actions to a creditor of the debtor's estate. Potential targets of the subject avoidance actions objected, arguing that such claims were nontransferable powers of the trustee rather than saleable estate property and urging the court to approve their competing settlement with the trustee. The U.S. Bankruptcy Court for the Western District of Pennsylvania disagreed with the potential defendants, holding that they lacked standing to object to the proposed sale, that avoidance actions are indeed estate property, and that the sale—rather than the settlement—best served the estate's interests. [read more …] U.S. Supreme Court Bankruptcy Roundup in Brief In Keathley v. Buddy Ayers Construction Inc., No. 25-6, 2026 WL 1686028 (U.S. June 11, 2026), the U.S. Supreme Court overturned a Fifth Circuit decision judicially estopping a chapter 13 debtor from asserting a personal injury claim against a construction company because the debtor failed to disclose the claim during his bankruptcy case. In so ruling, the Court held that "[t]he Fifth Circuit erred by artificially narrowing its inquiry to whether the debtor had knowledge of the underlying facts or a potential motive to conceal the claim." It represents the first time that the Court has applied judicial estoppel in the bankruptcy context, although it has suggested in other contexts that it may be inappropriate where an inconsistent legal position resulted from "inadvertence or mistake." Also in June, the Court denied petitions for certiorari in a few notable bankruptcy cases. [read more …] Newsworthy Heather Lennox (Cleveland/New York) (Star Individual), Bruce Bennett (Los Angeles) (Senior Statesperson), Kevyn D. Orr (Washington) (Eminent Practitioner), Gregory M. Gordon (Dallas) (Band 1), Carl E. Black (Cleveland), Corinne Ball (New York) (Senior Statesperson), Brad B. Erens (Chicago), Jeffrey B. Ellman (Atlanta), T. Daniel Reynolds (Cleveland), and Dan T. Moss (Washington/New York) were recognized as leading lawyers in the practice area Bankruptcy/Restructuring in the 2026 edition of Chambers USA: The World's Leading Lawyers for Business. The 2026 edition of Lawdragon 500 Leading Bankruptcy and Restructuring Lawyers ranked the following lawyers: Corinne Ball (New York) (Hall of Fame), Bruce Bennett (Los Angeles), Carl E. Black (Cleveland), Jeffrey B. Ellman (Atlanta), Brad B. Erens (Chicago), Gregory M. Gordon (Dallas), Heather Lennox (Cleveland/New York), Joshua M. Mester (Los Angeles), and Kevyn D. Orr (Washington). Fabienne Beuzit (Paris) and Jasper Berkenbosch (Amsterdam) were among the "Leading Individuals" ranked in the 2026 edition of The Legal 500 EMEA guide in the field of Restructuring and Insolvency or Insolvency. Rodolphe Carrière (Paris) was named a "Next Generation Partner" in the practice area Insolvency. Sid Pepels (Amsterdam) was selected by Global Restructuring Review's 40 under 40 2026. He was identified as a Rising Star within the global cross-border restructuring community. Global Restructuring Review is a leading digital subscription service, news outlet, and information platform dedicated exclusively to cross-border insolvency and corporate restructuring law. Fabienne Beuzit (Paris), Rodolphe Carrière (Paris), and Isabelle Maury (Paris) were recognized in the 2027 edition of The Best Lawyers in France™ in the practice area Insolvency and Reorganization Law. An article written by Corinne Ball (New York) titled "Comity and Fairness are Critical to Granting Additional Assistance under Chapter 15: A Canadian Reverse Vesting Order and Related Releases in Proceedings Involving Canadian and U.S.-Affiliated Companies Are Approved" was published in the June 24, 2026, edition of the New York Law Journal. An article written by Caitlin K. Cahow (Detroit) titled "New York Bankruptcy Court Weighs In on Adequate Assurance of Future Performance under Assigned Leases and Chapter 11 Plan Exculpation Provisions" was published on June 8, 2026, in Lexis Practical Guidance. An article written by Trisha L. Mowbray (Real Estate; Chicago) and Ryan Sims (Washington) titled "Chapter 11 Plan that Abridged Non-Debtor Lessee's Rights to Remain in Possession After Rejection Unconfirmable as Having Been Proposed in Bad Faith" was published on June 16, 2026, in the Harvard Law School Bankruptcy Roundtable. An article written by Dan T. Moss (Washington/New York), Corinne Ball (New York), Isel M. Perez (Miami), and David S. Torborg (Washington) titled "Texas Bankruptcy Court Adopts Barnet Rule Requiring Foreign Debtor to Have U.S. Assets to Be Eligible for Chapter 15 Relief" was published on June 10, 2026, in Lexis Practical Guidance. An article written by Daniel J. Merrett (Atlanta) and Nathaniel Parr (Atlanta) titled "Southern District of Texas Clarifies Post-Purdue Course for Consensual Third-Party Releases and Gatekeeping Provisions" was published on June 11, 2026, in Lexis Practical Guidance. An article written by Corinne Ball (New York) titled "LMEs, Sophisticated Investors and Equitable Mootness: The Fifth and Third Circuits Warn Against Testing the Limits of Chapter 11" was published in the June 2026 issue of the American Bankruptcy Institute Journal. Nicholas J. Morin (New York) was quoted in an article titled "Serta Ruling Offers Damages Road Map in Lender-on-Lender Disputes," published by Bloomberg Law on July 7, 2026. The article discussed U.S. Bankruptcy Judge Christopher Lopez's July 7, 2026, ruling that participating lenders in Serta Simmons Bedding's 2020 non-pro rata uptier exchange breached the credit agreement's ratable-sharing provision, and awarding excluded lenders more than $261 million in damages. The opinion resolves six years of litigation related to Serta's 2020 transaction, where it raised $200 million in new financing and exchanged $1.2 billion of term loans for $875 million in superpriority debt. Judge Lopez found that the debt-for-debt exchange constituted a "payment" under the credit agreement, requiring proportional sharing among lenders, and dismissed various defenses raised by the participating lenders. The case is Serta Simmons Bedding LLC v. AG Centre Street Partnership (In re Serta Simmons Bedding LLC), 2026 WL 1968535 (Bankr. S.D. Tex. Jul. 7, 2026). The New York Law Journal has recognized Andrew M. Butler (New York) as a 2026 "Rising Star" in Restructuring/Bankruptcy as part of the New York Legal Awards. The Rising Star category recognizes New York's most promising lawyers age 40 and under who have distinguished themselves through exceptional legal work, leadership, and contributions to the profession. Lawyer Spotlight: Daniel J. Merrett Dan Merrett, a partner in the Atlanta Office, has spent nearly 20 years representing all manner of stakeholders in complex corporate restructurings and chapter 11 reorganizations. His practice extends to related transactions and disputes involving acquisitions; divestitures; credit facilities; securities; environmental obligations; and vendor, employee, and governance matters. Dan has substantial experience managing mass tort liabilities, including the restructurings and related chapter 11 cases of affiliates of Georgia Pacific and Johnson & Johnson, implemented to resolve asbestos and talc liabilities. He also represents key parties in energy and infrastructure matters, including facility owners, EPC contractors, and joint-venture parties. Dan was a key player in the restructuring teams in the historic bankruptcies of the City of Detroit and Chrysler. His other significant representations in chapter 11 cases include AFA Foods, Alpha Natural Resources, Dana Corporation, M&G Chemicals, McDermott International, Monster/CareerBuilder, Transtar Industries, and Westinghouse. He is licensed in both the United States and England & Wales and recognized in restructuring by Chambers USA and Best Lawyers.
Court orders Instagram and Facebook's Meta to pay $567M to address kids' mental health online
Judge Bryan Biedscheid said in a ruling late Thursday that the bulk of the money will be used for treatment services for young people.
The Company Behind Ugly Gold Phones Is Now Making Ugly Gold Smart Glasses
Ray-Ban Meta AI glasses are getting the Caviar treatment.
Andrea Hennigan testifies on Lindsay Clancy's mental health and postpartum treatment
Registered nurse Andrea Hennigan testifies about her former colleague Lindsay Clancy. She describes Clancy's struggles with postpartum anxiety, insomnia, and medication side effects prior to January 2023.
AHF • ‘We the People’ Coalition Merges Faith & Politics to Engage Black Voters -- L.A. Gospel Concert & Panel, Sat., Aug. 8th
AIDS Healthcare Foundation (AHF), the world's largest HIV/AIDS healthcare organization, currently provides medical care and services to more than 1.75 million clients in 45 countries. With more than 7,000 employees worldwide, AHF now has treatment clinics and other operations in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region, and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth, and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.
Nearly half of dementia cases may be linked to risks you can change
A long-term brain study found that common risks such as smoking, high blood pressure, heart disease, and high blood lipids were strongly linked to damage associated with vascular dementia. The findings suggest that healthier lifestyle choices could help delay dementia by reducing several harmful brain changes at once.
Aware Recovery Care Caught in Multiple Financial, Operational Crises
Aware Recovery Care, a Connecticut-based addiction treatment provider with locations in 11 states, is embroiled in a tangle of legal issues and lost
NYC Health + Hospitals/Jacobi Unveils Art Exhibit for Behavioral Health Patients with Ribbon Cutting Ceremony
Bronx, NY – NYC Health + Hospitals/Jacobi’s Comprehensive Addiction Treatment Center (CATC) unveiled a new art exhibit from NYC Health + Hospitals’ art
Alec Baldwin’s daughter Ireland reacts to Perez Hilton’s hospitalization after his ‘unforgivable’ treatment of her
“I hope he gets the help he needs and heals,” wrote Ireland, who also dubbed the celebrity blogger “a despicable human being.”
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
Team's AI agent to speed Alzheimer's treatment
Vanderbilt researchers have received a grant to build an AI tool within the health record system to get patients with Alzheimer's disease to treatment faster.
Cold Spring Harbor Laboratory and Northwell Health lead international cohort of researchers to develop more than 150 next-generation cancer treatment models
Human Cancer Model Initiative releases compendium results of decade-long project to create cancer organoids Ten years and thousands of patient samples later, the National Cancer Institute (NCI) has just published its results from the Human Cancer Model Initiative (HCMI) on the development of 665 organoid models of 25 types of cancer that are now available...
THC medication made PTSD nightmares disappear for more than a third of patients
A prescription form of THC helped many people with PTSD escape recurring trauma-related nightmares, with more than one-third reporting that the nightmares disappeared completely after ten weeks. The results could point toward a long-awaited treatment for one of PTSD’s most distressing and stubborn symptoms.
'Brazilian blow-drying treatments ruined my life'
Former hairdresser Louisa Curtis says exposure to formaldehyde gas left her unable to work.
AI generates personalized radiopharmaceutical therapy doses in under 23 seconds
The model has the potential to improve upon the one-size-fits-all dosing approach used for most RPT prostate cancer treatments.
Stanford scientists discover immune cells that explode like microscopic bombs
Stanford researchers discovered immune cells in flatworms that explode within minutes, killing nearby bacteria and foreign cells before vanishing completely. Their unusually fast and localized attack could offer clues for developing targeted treatments against infections and cancer.
In New York, Mental Health Diversion Depends on Your County
Half of New York counties lack mental health courts, limiting treatment-based alternatives to jail.
Rep. Edwards’ behavior with staffers violated House code of conduct, panel finds
The House Ethics Committee released a report Monday in its investigation into the western North Carolina lawmaker's treatment of two female staffers.
Trump administration sued for banning gender transition treatments in federal health plans
An arm of the Human Rights Campaign launched a class-action lawsuit on Monday challenging the Trump administration’s gender-affirming care coverage ban in federal workers’ health insurance plans.&n…
SAMHSA awards $73 million in grants for children’s mental health, other programs
The Substance Abuse and Mental Health Services Administration announced July 31 that it awarded $73.2 million in grants for children’s mental health, suicide prevention and assisted outpatient treatment programs.
New study torpedoes mental health treatment mandate
The first-of-its-kind evaluation of Kendra’s Law was commissioned at the direction of the state Legislature.
Intermountain Health introduces new pancreatic cancer drug in western Colorado
Cancer center offering first-in-class treatment shown to more than double patients' expected length of life
Johnson County Criminal Mental Health Court would offer treatment plans instead of jail time
Johnson County is considering adding a criminal mental health court program aimed at helping repeat offenders with serious mental illness.
Cancer may be breaking its own DNA to keep growing
Cancer cells rely on powerful genetic switches to keep growth genes running at full speed, but that intense activity can damage their own DNA. The resulting breaks are repeatedly repaired, sometimes with small mistakes that allow new mutations to accumulate. Researchers believe this self-inflicted damage may help tumors evolve while also creating a potential target for new treatments.
Panama: Haemophilus influenzae meningitis case reported in Veraguas Health Region
The Veraguas Health Region, located in the central-western region of Panama, confirmed a case of meningitis caused by the Haemophilus influenzae bacteria in a 12-year-old student from La Primavera School, diagnosed on July 29. The patient remains hospitalized, is receiving appropriate treatment, and is in stable clinical condition. The regional health director of Veraguas, Xavier A. Torres Domínguez, reported that, once the diagnosis was confirmed, the Ministry of Health (Minsa), in coordination with the Social Security Fund (CSS), immediately activated the epidemiological investigation and health response protocols established for this type of event. Canada: Haemophilus influenzae type B outbreak in Calgary As part of the actions implemented, the Epidemiology teams carried out the identification and monitoring of the patient’s close contacts, applying the corresponding preventive measures to reduce the risk of transmission and safeguard the health of the educational community. Health authorities explained that meningitis caused by Haemophilus influenzae is a bacterial disease that requires timely medical attention. In that regard, they urged the population to immediately seek medical attention if they experience symptoms such as high fever, severe headache, stiff neck, vomiting, drowsiness, or altered mental status. They also reiterated that vaccination is the main preventive measure against this disease, and therefore called on parents and guardians to verify that their children’s immunization schedules are complete, in accordance with the Expanded Program on Immunization (EPI). Outbreak News Today is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber. Subscribe
Could we prevent dementia? A new trial may point the way.
While much funding for dementia research goes toward treatments, some scientists want to reduce people's risk of developing the condition in the first place.
Scientists may have found a way to prevent statin muscle pain
Scientists have identified an immune response that may explain why statins cause muscle pain, weakness, and exercise intolerance in some people. The finding could eventually lead to treatments that protect muscles while preserving the drugs’ lifesaving cardiovascular benefits.
FDA clears autoinjector drug for home treatment of heart failure edema
A new drug delivery system may help reduce heart failure hospitalizations and related healthcare costs, which are expected to reach $70 billion by 2030.
Beyond 'healthy' obesity: New framework weighs organ damage and daily limitations
A new approach to defining obesity could help physicians better determine which patients need more intensive treatment by focusing on the effects of excess adiposity on organs and tissues rather than ...
SAMHSA Awards $73.2 Million for Mental Health Treatment and Suicide Prevention Programs
HHS announced awarded $73.2 million in grants to strengthen children’s mental health services, suicide prevention programs.
Does public health *need* MAHA?
Last week, our friend Dr. Craig Spencer sparked an ongoing volatile discussion with his Atlantic article “Public Health Needs MAHA.” Some have come out in strong dissent, others are cheering, and others are simply lamenting that we find ourselves in such a divided world to begin with. We will dare to dip our toes in these controversial waters, too. Does public health need MAHA? We think in some ways yes, and in other ways, no. MAHA leaders versus the everyday MAHA supporter The vitriol in this debate mostly comes from one collapsed distinction: the leadership of MAHA is not necessarily the same as the people who support it. Say “MAHA” and most people picture RFK Jr. Fair enough, as he coined the term and holds most of the power. And, yes, some MAHA followers treat Kennedy as something close to a saint. But talk to the grassroots, and it’s not a monolith. They’re Republicans, Democrats, and Independents. People who distrust vaccines and vaccine supporters. It’s a wide, eclectic coalition. The data backs this too: 4 in 10 Americans support the movement—that’s a lot of people! But according to polls, vaccines and medical choice (the issues most tied to Kennedy personally) are cited by only 4% as their reason for supporting the movement. For many, the motivations are much broader. Many MAHA supporters are signing up for the idea that “something needs to change” with health in this country. They’re asking good-faith questions about corporate influence on our health systems, health care costs, nutrition, chemicals, and clean air and water. These are all questions that plenty of public health professionals recognize as legitimate and also care about very deeply. Blurring the lines between the leadership and grassroots does real damage in two important ways: It hands the 4 in 10 exactly the narrative already fed—that the health ecosystem doesn’t listen, doesn’t care, and paints every critic with the same brush. It gives the actual bad actor more power. RFK Jr. has done irreparable damage and can’t be trusted. What the MAHA movement gets right A healthy population is something the public health field was literally built on, and many of these topics are things we have dedicated our lives to. Yet the MAHA movement has captivated nearly half the country in a way the public health establishment has failed to achieve. So that means MAHA is doing something right. Some of it may be timing (after a Covid-19 pandemic and deep frustration and mistrust with institutions). The movement also does three other things really well: 1. It gives a new, louder voice to system failures. While MAHA is not a monolith, one theme stays consistent across their stories: the system failed them. For some, it was the system that flooded their communities with opioids and then walked away. For others, it was the system that let their business collapse during Covid with no safety net in sight. For others still, it was the system that failed to help them manage a complex chronic illness, bouncing them from physician to physician without any real answers. And in many ways, our health ecosystems are failing Americans. Why are medical bills so incomprehensible? Why do some kids get a healthy school lunch and others don’t? Why do an epidemiologist and a MD/PhD student have to start newsletters in the middle of the biggest public health emergency in a century, just so people can get straight information? Because the systems failed. This deep-seated frustration driving many Americans to search for solutions elsewhere needs to be recognized. 2. MAHA has brilliant comms central to their efforts. MAHA figured out something most health institutions still have not: the information landscape changed. It’s participatory now, not top-down; influence runs through many nodes in a community, not one institution; and storytelling and telling audiences “what you really think” moves people more than data dumps do. MAHA goes where audiences are listening, using podcasts, social media, and memes in ways most health institutions would scoff at—but it works. 3. They are very good at organizing. A MAHA meeting feels like a rally: energy, speakers, music, and most importantly, an action for everyone. Someone’s writing the next policy brief, someone’s seeding a narrative, someone knows the next legislative deadline, someone’s sending the text messages for a campaign. None of this is new (ask the civil rights movement), but MAHA knows it works and has capitalized on it. What MAHA gets wrong This list could be much longer, and this newsletter has spent a lot of time covering it, but here are a few things: Poor use of scientific evidence. This is the fundamental problem with many MAHA policies: the hype outpaces the science, and experts are often villainized for pointing this out. MAHA leadership has traded real solutions for cheap wins. For example, instead of taking on the powerful food industry and passing real reforms, it has celebrated french fries made of beef tallow and taken out artificial dyes from still very sugary children’s cereal. These changes won’t move the needle on America’s diet. MAHA leadership has tried to dismantle vaccine access in the U.S. While many MAHA supporters emphasize other issues, the effort to change vaccine policy has become MAHA’s signature effort. This is not surprising given RFK Jr.’s extensive track record campaigning against vaccines. It has rallied behind the wrong leader. RFK Jr. has a decades-long track record of villifying doctors, scientists, and public health workers, well before he became HHS secretary. He is known for his decades-long work sowing distrust in vaccines as well as life-saving treatments like antiretroviral therapy for HIV. This is not a serious person who can move the needle on health in the U.S, and he has already done serious damage. Public health needs more than defense Defending the evidence is absolutely necessary so health in the U.S. doesn’t move further backward. The public health establishment is very good at defense. The problem is this defense often sounds like defending the status quo, which has failed many people. Public health needs to offer an alternative to RFK Jr.’s MAHA—one that is rooted in evidence, truly listens to and addresses people’s frustrations, and has innovative solutions and the courage to change the systems. How do we get there? Find common ground. Do you know what most people care most about? The abysmal cost of healthcare. Start there. Fight for the human loudly. Too often, communications and engagement center on science with a capital S, funding mechanisms, or the CDC/FDA/NIH. Not the person. So the public doesn’t see themselves in it. Instead, they see people fighting for the very powerful systems that they feel negatively impact their health and well-being. Let the public feel and hear that you see their frustrations, you get it, and you’re fighting for them within the system. Recognize when pro-science messages are alienating people. Facts absolutely matter, but angrily venting only alienates people further. Our friend Elisabeth Marnik recently wrote a New York Times article about her experience growing up unvaccinated and how listening and empathetic conversation are the only ways to reach people that really work (a position backed by communication science). Her comments section was full of hateful comments from pro-vaccine individuals attacking her for daring to suggest we approach vaccine-hesitant individuals with empathy. It is possible to both stand firm behind scientific evidence and empathize with people who don’t trust it. Lean into politics smartly. Often, public health has shied away from politics: Don’t touch it, lest you get burned. But this fails to recognize that the third rail is what fuels the train: who is elected determines our budgets, our priorities, and our authority. Being political means being very savvy in strategy on both sides of the aisle, knowing your audience, and recognizing that political capital is as scarce as financial resources and needs to be allocated accordingly. Bottom line So does public health need MAHA? That’s not really the right question. Public health has a responsibility not to dismiss 40% of the country who feel heard by this movement and are frustrated that the system has failed them. And it has a responsibility to stick to the evidence and recognize MAHA leadership for what it is: a danger to our nation’s health. Both can, and should, be done. Love, YLE and KP A big thanks to Craig Spencer, who had the courage to put his neck out there to start a much-needed discussion at such a critical moment—one that is determining the identity of an entire field. Kristen Panthagani, MD, PhD is completing an emergency medicine residency and research fellowship focusing on health literacy and communication. In her free time, she writes the newsletters You Can Know Things debunking health myths and rumors and The Public Health Roundup. Views expressed belong to KP, not her employer. Your Local Epidemiologist (YLE) comprises a team of experts, ranging from physicians to immunologists to epidemiologists to nutritionists, working together with one goal: to “translate” ever-evolving public health science so that people are well-equipped to make evidence-based decisions. The YLE suite of newsletters reaches over 475,000 people across more than 132 countries. This newsletter is free to everyone, thanks to the generous support of fellow YLE community members. To support the effort, subscribe or upgrade below: Subscribe